MSD
Clinical Trials
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
CLINICALTRIALS.GOV IDENTIFIER
NCT02628067
EudraCT Number
2015-002067-41
EU CT Number
2022-500397-34-00
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Advanced Cancer, Advanced Solid Tumors, Anal Cancer, Anal Carcinoma, Bile Duct Cancer, Biliary Cancer, Carcinoid Tumor, Cervical Cancer, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Endometrial Cancer, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Tumor, Parotid Gland Cancer, Salivary Cancer, Salivary Gland Cancer, Salivary Gland Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Thyroid Cancer, Thyroid Carcinoma, Vulvar Cancer, Vulvar Carcinoma
Age Range
18+
Sex
All
Current trial phase
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about